Akero Therapeutics is a clinical-stage biotechnology company developing transformative therapies for serious metabolic diseases, with a focus on non-alcoholic steatohepatitis (NASH). Their lead product candidate, Efruxifermin (EFX), is an engineered Fc-FGF21 fusion protein designed to mimic the bioactivity of natural FGF21, which has shown potential to reverse fibrosis, reduce liver fat, improve glycemic control, and reduce weight in clinical trials. Akero aims to address the significant unmet medical need in NASH, a disease with no approved therapies and a growing global patient population.
7 answers
Maria
Sat Oct 26 2024
The focus is on individuals suffering from severe metabolic diseases.
Maria
Sat Oct 26 2024
The company aims to improve the quality of life for these patients.
SumoPowerful
Sat Oct 26 2024
Through its research and development efforts, Akero hopes to bring about positive changes.
CherryBlossom
Sat Oct 26 2024
Akero is at the forefront of developing innovative treatments.
DongdaemunTrendsetting
Sat Oct 26 2024
Another entity in the crypto space, BTCC, offers a range of services.